Factor Model (net +1.3)
Factor Model
net +1.3 3.1 / 10FDA lifts nex-z clinical holds; 47% YTD rally stands
Watch: Monitor nex-z phase 3 enrollment and interim data readouts over the next 12-18 months. Any new liver events or regulatory concerns will reverse this signal and risk the stock's recent gains.
Intellia's shares have climbed 47% this year, driven by FDA clearance to resume two phase 3 studies for nex-z after lifting clinical holds imposed following a patient death. The agency's decision signals the company persuaded regulators that drug-related causation remains unproven and that tighter liver-function monitoring and patient-selection criteria mitigate risk. This regulatory win removes a major overhang that froze development momentum in 2024.
The hold lift unblocks a critical pipeline asset and justifies the year's rally, but uncertainty persists — causation in the patient's liver failure has not been conclusively determined. Nex-z success is now contingent on trial execution; any new safety signals could reignite holds. For runway, this reduces binary event risk in the near term, giving LONVO-Z commercial launch the runway to prove out the platform.
Evidence
Fundamentals & Data ▾
Recent transactions
Get alerted when NTLA changes direction
We'll email you when our AI detects a shift — reversals, insider clusters, filing red flags.